ArticleJournal of clinical microbiology2008
Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.
Article in Journal of clinical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed.
- Variety ofGerms · 2026Article
- Differences in virulence and drug resistance betweenVirulence · 2025Article
- A Colombian strain ofVirulence · 2025Article
- The phi027 bacteriophage influences physiology and virulence of the lysogenic strain of Clostridioides difficile.Scientific reports · 2025Article
- In-depth characterization of accessory gene regulator loci and associated virulence factors inCurrent research in microbial sciences · 2025Article
- Prevalence of toxigenicThe Libyan journal of medicine · 2024Article
- "Antibiotics (Basel, Switzerland) · 2024Article
- Review
- Advances in diagnostic assays forFrontiers in cellular and infection microbiology · 2024Review
- Clostridioides difficile Sporulation.Advances in experimental medicine and biology · 2024Review
- One size does not fit all - Trehalose metabolism byMicrobial genomics · 2023Article
- Insights into the Evolving Epidemiology ofAntibiotics (Basel, Switzerland) · 2023Review
- Identification of novel p-cresol inhibitors that reduce Clostridioides difficile's ability to compete with species of the gut microbiome.Scientific reports · 2023Article
- Molecular epidemiology of community- and hospital-associated Clostridioides difficile infections in Jönköping, Sweden, October 2017 - March 2018.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Article
- Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.Letters in applied microbiology · 2022Review
- Opportunities for Nanomedicine inAntibiotics (Basel, Switzerland) · 2021Review
- Temporal Variations in Patterns ofAntibiotics (Basel, Switzerland) · 2021Article
- Soluble Non-Starch Polysaccharides From Plantain (Frontiers in pharmacology · 2021Article
- External validation of two prediction tools for patients at risk for recurrentTherapeutic advances in gastroenterology · 2021Article
- Production ofFrontiers in cellular and infection microbiology · 2021Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile PCR ribotype 027 comprised 0.2% of a collection of Swedish isolates in 1997-2001 (3 of 1,325 isolates). These isolates had lower moxifloxacin MICs than the epidemic type 027 isolates, but they had the same tcdC sequence and toxin yield. Type 027 produced 3- to 13-fold more toxin than did major Swedish types. One epidemic strain (027/NAP1a) sporulated more than did other type 027 isolates, a feature that should contribute to its survival and spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.